Covid 19 among healthcare professionals
Not Applicable
Completed
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: J22- Unspecified acute lower respiratory infection
- Registration Number
- CTRI/2021/01/030242
- Lead Sponsor
- Instituton Pramukhswami Medical College Karamsad
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
Inclusion: All healthcare professionals admitted at Shree Krishna Hospital who have had suffered from COVID 19 (RT-PCR positive) during the period of 1st March 2020 to 31st December, 2020.
Exclusion Criteria
All healthcare professionals who have taken treatment on outdoor basis.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical profile of COVID among healthcare professionalsTimepoint: at baseline, during course of illness, at the time of discharge from the hospital
- Secondary Outcome Measures
Name Time Method Response to therapy and Post traumatic stress disorder among healthcare professionals afflicted with COVID 19Timepoint: At least after 3 weeks post discharge
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms contribute to SARS-CoV-2 susceptibility in healthcare professionals with acute lower respiratory infection (J22)?
How does adherence to PPE protocols correlate with reduced SARS-CoV-2 transmission among healthcare workers in observational studies?
Which biomarkers (e.g., ACE2 expression, cytokine profiles) predict severe COVID-19 outcomes in CTRI/2021/01/030242 participants?
What adverse events are most commonly reported in healthcare professionals with B972-related infections and how are they managed?
How do antiviral therapies like remdesivir compare to standard care in mitigating J22 symptoms among CTRI/2021/01/030242 cohort?